Aspire Biopharma Holdings (ASBP) Total Liabilities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Total Liabilities for 6 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 83.19% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 83.19% decrease from a year earlier, with the FY2025 full-year figure at $7.7 million, up 355.46% from the prior year.
• Total Liabilities was $1.8 million for Q2 2026 at Aspire Biopharma Holdings, down from $3.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $13.9 million in Q3 2025 and troughed at $284356.0 in Q2 2023.
• A 5-year average of $6.4 million and a median of $7.0 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 3929101.79% in 2022 and slumped 97.41% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $11.1 million in 2022, then slumped by 96.37% to $403328.0 in 2023, then surged by 318.54% to $1.7 million in 2024, then jumped by 355.46% to $7.7 million in 2025, then sank by 76.81% to $1.8 million in 2026.
• The last three Total Liabilities figures came in at $1.8 million (Q2 2026), $3.2 million (Q1 2026), and $7.7 million (Q4 2025), per Business Quant data.